Related Experiment Video
Updated: Jun 19, 2026

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 25, 2010
Functional and Clinical: An Explainable Deep Learning Model for Multimodal Alzheimer's Disease Classification
Samuel L Warren1, Ahmed A Moustafa1,2
1School of Psychology, Faculty of Society and Design, Bond University, Gold Coast, Queensland, Australia.
Brain and Behavior
|January 30, 2026
Summary
Combining functional magnetic resonance imaging (fMRI) with clinical data significantly improves Alzheimer's disease (AD) classification using deep learning. This multimodal approach enhances model accuracy and explainability for better clinical application.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Clinical Diagnostics
Background:
- Deep learning models using fMRI show promise for Alzheimer's disease (AD) classification.
- Challenges include small datasets, lack of explainability, and reliability issues like data leakage, hindering clinical adoption.
Purpose of the Study:
- To develop a reliable and explainable multimodal deep learning model for AD classification.
- To address limitations of fMRI-based models by integrating clinical data and employing explainable AI (XAI).
Main Methods:
- A 3D convolutional neural network was trained on fMRI data from the default mode network and five clinical tests.
- Multimodal data integration and a strict leave-one-out cross-validation were used to overcome data limitations and prevent data leakage.
- Perturbation ranking was applied for feature importance analysis.
Main Results:
- The multimodal model achieved 90% accuracy in classifying AD from controls, significantly outperforming models using only fMRI (58% accuracy).
- Feature importance varied by diagnostic group, with clinical tests like the MoCA showing differential relevance for controls versus AD patients.
- Explainable AI revealed distinct patterns of feature importance across clinical and fMRI data.
Conclusions:
- Combining fMRI and clinical data in a multimodal deep learning model enhances AD classification accuracy and provides insights into disease characteristics.
- The developed model demonstrates potential for refining diagnostic tools for Alzheimer's disease.
- Further external validation with larger sample sizes is recommended.
Related Concept Videos
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
